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The cutaneous lymphatic system plays an important role in the maintenance of tissue fluid homeostasis, in the
afferent phase of the immune response, and in the metastatic spread of skin cancers. However, the lymphatic
system has not received as much scientific attention as the blood vascular system, largely due to a lack of
lymphatic-specific markers and to the dearth of knowledge about the molecular regulation of its development
and function. The recent identification of genes that specifically control lymphatic development and the growth
of lymphatic vessels (lymphangiogenesis), together with the discovery of new lymphatic endothelium-specific
markers, have now provided new insights into the molecular mechanisms that control lymphatic growth and
function. Moreover, studies of several genetic mouse models have set the framework for a new molecular
model for embryonic lymphatic vascular development, and have identified molecular pathways whose
mutational inactivation leads to human diseases associated with lymphedema. These scientific advances have
also provided surprising evidence that malignant tumors can directly promote lymphangiogenesis and
lymphatic metastasis, and that lymphatic vessels play a major role in cutaneous inflammation and in the
cutaneous response to UVB irradiation.
Journal of Investigative Dermatology (2006) 126, 2167–2177. doi:10.1038/sj.jid.5700464
Physiology and anatomy
Apart from the cardiovascular system,
higher vertebrates also possess a lym-
phatic system that consists of the
lymphatic vessels and the lymphoid
organs that include lymph nodes, ton-
sils, Peyer’s patches, spleen, and thy-
mus. Whereas the cardiovascular
system forms a closed circle around
which blood is pumped by the heart,
the lymphatic system comprises a one-
way, open-ended network without a
central driving force. Lymph, a protein-
rich exudate from blood vessels, is
taken up by the lymphatic capillaries
in the tissue. From there it is returned to
the venous circulation via the larger
collecting lymphatic vessels and the
thoracic duct, which connects the
lymphatic system to the inferior vena
cava (Figure 1). The pressure gradients
to move lymph through the vessels
result from skeletal muscle action,
respiratory movement, and contraction
of smooth muscle cells in vessel walls.
The lymphatic system also contributes
to the immune surveillance of the
body. Lymphatic vessels transport im-
mune cells – including lymphocytes
and antigen-presenting dendritic cells –
from the skin to regional lymph nodes,
where specific immune responses
are initiated. In addition, the lacteal
lymphatic vessels of the intestine are
involved in the uptake of dietary fat
and of the fat-soluble vitamins A, D, E,
and K from the digestive system. How-
ever, recent scientific discoveries have
revealed that the lymphatic system also
plays a major role in a number of
pathologic conditions, including lymph-
edema, inflammatory diseases, and
tumor metastasis.
Lymphatic vessels are present in
almost all tissues but are absent from
avascular structures such as the epider-
mis, hair, nails, cartilage, and cornea,
and from some vascularized organs
such as the brain and retina. In the
skin, the superficial lymphatic plexus
collects lymph from lymphatic capil-
laries that can extend into the dermal
papillae. These lymphatic capillaries
are lined by a single, non-fenestrated
layer of overlapping endothelial cells,
and – in contrast to blood vessels – lack
a continuous basement membrane as
well as pericyte or smooth muscle cell
coverage. Lymphatic endothelial cells
(LECs) are connected to the surround-
ing extracellular matrix by specialized
fibrillin-containing anchoring filaments
(Gerli et al., 2000). Upon increase of
interstitial fluid pressure, these fila-
ments exert tension on LECs, thereby
widening the capillary lumen and
opening the overlapping cell junctions,
which enables the uptake of fluid,
macromolecules, and cells. The larger
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collecting lymphatic vessels in the
lower dermis and upper subcutis are
surrounded by a basement membrane
and by a layer of smooth muscle cells
that contribute to lymph propulsion.
They contain luminal valves to ensure
unidirectional fluid transport.
Embryonic development
The first description of the lymphatic
system dates back to the seventeenth
century, when the Italian anatomist
Gasparo Aselli identified lymphatic
vessels as ‘‘milky veins’’ in the mesen-
tery of a ‘‘well-fed’’ dog (Asellius,
1627). However, the developmental
origin of lymphatic vessels remained
unclear until Florence Sabin proposed
in 1902 – based upon ink-injection
experiments in pigs – that endothelial
cells bud off from the veins during early
embryonic development and form pri-
mitive lymph sacs. The peripheral
lymphatic system then originates from
these primary lymph sacs by endo-
thelial sprouting into the surrounding
tissues and organs, where local capil-
laries are formed (Sabin, 1902). This
model was challenged in 1910 by
Huntington and McClure who alternat-
ively suggested that lymph sacs arise –
independently of the veins – from
mesenchymal precursor cells (lym-
phangioblasts), with consecutive
establishment of venous connections
(Huntington and McClure, 1910). Re-
cent studies in genetically engineered
mouse models have now provided
clear evidence for the origin of the
mammalian lymphatic system from
embryonic veins (Oliver, 2004), and
they have also identified some of the
molecular determinants that control the
step-wise process of lymphatic compe-
tence, commitment, differentiation and
maturation (Figure 2).
Novel molecular markers of lymphatic
endothelium
Major advances in lymphatic research
have been made possible by the recent
establishment of defined cultures of
blood vascular endothelial cells (BECs)
and LECs isolated from human skin
(Kriehuber et al., 2001; Makinen
et al., 2001; Podgrabinska et al.,
2002; Hirakawa et al., 2003). These
cells maintain their lineage-specific
differentiation even after several pas-
sages in vitro. Comparative microarray
analyses of their specific transcrip-
tomes revealed that the majority of all
genes investigated (appr. 98%) were
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Figure 1. Schematic illustration of the blood vascular and lymphatic system. The blood vascular system
is a circular and closed system, whereas the lymphatic system is open-ended and linear. Fluids,
macromolecules, and cells extravasated from blood capillaries enter lymphatic capillaries in peripheral
tissues and are then transported via the larger collecting lymphatic vessels and the thoracic duct back
to the blood vascular system for recirculation.
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Figure 2. Current model of the stepwise embryonic development of the mammalian lymphatic system. During early vascular development, all endothelial cells
of the embryonic cardinal vein express two important lymphatic markers, lymphatic vascular endothelial hyaluronan receptor (LYVE-1) and VEGFR-3, and
display lymphatic competence. Stimulation by a yet unidentified inductive mesenchymal signal leads to induction of the transcription factor Prox1 in a subset
of endothelial cells that become committed to the lymphatic lineage. These cells bud off from the vein and migrate into the surrounding tissue to form
primitive lymph sacs. During this process, they adopt the expression of additional lymphatic lineage markers. The formation of a mature lymphatic network
continues through the first postnatal days.
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expressed at comparable levels by
the two endothelial cell types (Petrova
et al., 2002; Hirakawa et al., 2003),
corroborating their close genetic rela-
tionship. However, these studies have
also identified numerous, previously
unknown lineage-specific markers for
blood vascular and lymphatic endo-
thelium (Table 1). Whereas the specific
function of the majority of the differen-
tially expressed genes still remains
unknown, the study of several lymph-
atic-specific molecules has provided
important new insights into the mole-
cular control of lymphatic develop-
ment and function (Table 2).
Vascular endothelial growth factor
receptor-3 (VEGFR-3), also known as
Flt4, was the first lymphatic-specific
growth factor receptor identified
(Kaipainen et al., 1995). VEGFR-3 is
a member of the fms-like tyrosine
kinase family and specifically binds
vascular endothelial growth factor
(VEGF)-C and VEGF-D, but not
VEGF-A. During early embryonic de-
velopment, VEGFR-3 is expressed both
Table 1. Specific markers for LV versus BV
Markers Function LV BV References
Prox1 Transcription factor ++  (Wigle and Oliver, 1999)
Podoplanin Transmembrane glycoprotein ++  (Wetterwald et al., 1996;
Breiteneder-Geleff et al., 1999)
LYVE-1 Hyaluronan receptor ++  (Banerji et al., 1999)
VEGFR-3 Growth factor receptor + /(+)1 (Kaipainen et al., 1995)
Neuropilin-2 Semaphorin and growth factor receptor + /(+)2 (Yuan et al., 2002)
Macrophage mannose
receptor 1
L-selectin receptor +  (Irjala et al., 2001)
CCL21 CC-chemokine +  (Gunn et al., 1998)
CCL20 CC-chemokine + (++)3  (++)3 (Kriehuber et al., 2001;
Hirakawa et al., 2003)
Desmoplakin Anchoring protein of adhering junctions +  (Ebata et al., 2001)
Plakoglobin Connect cadherins to cytoskeleton in cell–cell junctions +  (Petrova et al., 2002; Hirakawa et al., 2003)
Integrin a9 Adhesion molecule, subunit of osteopontin
and tenascin receptors, VEGFR-3 coreceptor?
+  (Huang et al., 2000; Petrova et al., 2002)
CD44 Hyaluronan receptor  + (Kriehuber et al., 2001)
VEGF-C Growth factor  + (Kriehuber et al., 2001;
Hirakawa et al., 2003)
VEGFR-1 Growth factor receptor  + (Hirakawa et al., 2003)
Neuropilin-1 Semaphorin and growth factor receptor  + (Hong et al., 2002; Petrova et al., 2002)
Endoglin/CD105 Low-affinity receptor for TGF-b  ++ (Hirakawa et al., 2003)
CD34 L-selectin receptor /(+)4 ++ (Young et al., 1995)
IL-8 CXC-chemokine  + (Petrova et al., 2002)
N-cadherin Adhesion molecule  + (Petrova et al., 2002; Hirakawa et al., 2003)
ICAM-1/CD54 Adhesion molecule  + (Erhard et al., 1996)
Integrin a5 Adhesion molecule, subunit of fibronectin receptor  + (Petrova et al., 2002; Hirakawa et al., 2003)
Collagen IV Extracellular matrix protein /(+)5 ++ (Hirakawa et al., 2003)
Versican Chondroitin sulfate proteoglycan  + (Petrova et al., 2002; Hirakawa et al., 2003)
Laminin Basement membrane molecule /(+)5 ++ (Barsky et al., 1983; Petrova et al., 2002)
Collagen XVIII Basement membrane molecule /(+)5 ++ (Petrova et al., 2002; Hirakawa et al., 2003)
PAL-E Caveolae-associated glycoprotein?  ++ (Schlingemann et al., 1985;
Niemela et al., 2005)
BV, blood vessel; CCL, CC chemokine ligand; LV, lymphatic vessel; LYVE-1, lymphatic vascular endothelial hyaluronan receptor-1; PAL-E, pathologische
anatomie leiden-endothelium; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
1VEGFR-3 expression was also found on some blood capillaries during tumor neovascularization and in wound granulation tissue (Valtola et al., 1999;
Paavonen et al., 2000).
2Neuropilin-2 is also expressed in veins (Yuan et al., 2002).
3After activation, both blood vascular and lymphatic endothelial cells strongly express CCL20 (Kriehuber et al., 2001).
4CD34 expression has also been found on lymphatic endothelial cells (Sauter et al., 1998; Kriehuber et al., 2001).
5Peripheral lymphatic vessels sometimes have an incomplete basement membrane, large collecting vessels a complete one.
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in developing venous and in presump-
tive lymphatic endothelia. In normal
adult tissues, VEGFR-3 expression
is largely restricted to the lymphatic
endothelium (Kaipainen et al., 1995;
Partanen et al., 2000). However,
VEGFR-3 expression has also been
detected on some blood capillaries
associated with tumor neovasculariza-
tion or with wound granulation tissue
(Partanen et al., 1999; Paavonen et al.,
2000); therefore VEGFR-3 alone is
not a sufficiently specific marker for
lymphatic vessels.
The transcription factor Prox1 is a
homolog of the Drosophila homeobox
gene prospero (Oliver et al., 1993). At
present, it is considered as the most
specific lineage marker for lymphatic
endothelium – among endothelial cells,
it is exclusively detected in lymphatic
vessels of adult tissues and tumors
(Oliver and Detmar, 2002). During
lymphatic development, Prox1 expres-
sion is induced in lymphatically ‘‘com-
petent’’ endothelial cells at one side
of the cardinal vein around mouse
embryonic day (E) 9.5–E10.5 by a
presently unknown signal, leading to
lymphatic commitment and specifica-
tion (Figure 2). In Prox1 null mice,
budding and sprouting of these cells
from the veins is arrested prematurely
at around E11.5–E12.0, and as a result,
these mice completely lack lymphatic
vasculature (Wigle and Oliver, 1999)
(Table 2). In Prox1 null mice, the
budding endothelial cells fail to express
lymphatic endothelial markers (Wigle
et al., 2002). Conversely, ectopic ex-
pression of Prox1 in differentiated BECs
is sufficient to reprogram these cells to
Table 2. Genetic mouse models with abnormalities of the lymphatic system
Genes Function Models Phenotype References
Integrin a9 Adhesion receptor KO Respiratory failure caused by pleural fluid
(chylothorax), lymphedema
(Huang et al., 2000)
Angiopoietin-1 Growth factor TG Hyperplastic lymphatic vessels (Tammela et al., 2005)
Angiopoietin-2 Growth factor KO Chylous ascites and peripheral edema, abnormal
patterning of lymphatic vasculature
(Gale et al., 2002)
VEGF-C Growth factor TG Hyperplastic lymphatic vessels (Jeltsch et al., 1997)
VEGF-C Growth factor KO No lymphatic vasculature (/), delayed
lymphatic vascular development, lymphatic
hypoplasia and lymphedema (+/)
(Karkkainen et al., 2004)
HGF Growth factor TG Enhanced formation and enlargement of
lymphatic vessels
(Kajiya et al., 2005)
VEGFR-3 Growth factor receptor KO Cardiovascular failure, defective remodelling of
vascular networks
(Dumont et al., 1998)
VEGFR-3 Growth factor receptor Chy mice
(inactivating
mutation)
Lymphedema (Karkkainen et al., 2001)
Neuropilin-2 Growth factor receptor KO Absence or severe reduction of small lymphatic
vessels and capillaries during development
(Yuan et al., 2002)
Prox1 Transcription factor KO No lymphatic vasculature (/), adult-onset
obesity, chylous ascites (+/)
(Wigle and Oliver 1999;
Harvey et al., 2005)
FOXC2 Transcription factor KO Lymphatic hyperplasia (+/), abnormal
patterning and pericyte investment of lymphatic
vessels, agenesis of valves, lymphatic
dysfunction (/)
(Kriederman et al., 2003;
Petrova et al., 2004)
Net (Elk3) Transcription factor KO Chylothorax, dilated lymphatic vessels (Ayadi et al., 2001)
SOX18 (ragged) Transcription factor KO (spontaneous
missense
mutations)
Edema, chyle accumulation in the peritoneum,
cardiovascular and hair follicle defects
(Pennisi et al., 2000)
Podoplanin Membrane glycoprotein KO Lymphedema, dilation of lymphatic vessels,
abnormal patterning
(Schacht et al., 2003)
Syk and SLP-76 Tyrosine kinase (Syk),
adaptor protein (SLP-76)
KO Abnormal blood-lymphatic connections,
chylous ascites
(Abtahian et al., 2003)
Ephrin B2 Ligand of EphB receptors Mutant lacking
PDZ interaction
site
Defective remodelling of lymphatic vascular
network, hyperplasia, lack of valves,
chylothorax
(Makinen et al., 2005)
FOXC2, forkhead box C2; HGF, hepatocyte growth factor; KO, knock-out; PDZ, PSD-95, DISCS-large, and Zo-1; SLP, Src homology 2-domain containing
leukocyte protein; SOX18, sex determining region Y-related high mobility group box 18; TG, transgenic; VEGF, vascular endothelial growth factor; VEGFR,
vascular endothelial growth factor receptor.
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adopt a lymphatic phenotype (Hong
et al., 2002; Petrova et al., 2002).
Prox1þ / mice die within 2–3 days
after birth in all of the tested genetic
backgrounds except one (Wigle and
Oliver, 1999), in which they develop
chylous ascites and – interestingly –
adult onset obesity, suggesting a link
between impaired lymphatic function
and obesity (Harvey et al., 2005).
Lymphatic vascular endothelial hya-
luronan receptor-1 (LYVE-1), a homo-
logue of the blood vascular
endothelium-specific hyaluronan re-
ceptor CD44 (Banerji et al., 1999),
was identified as a specific cell surface
protein of LECs and macrophages. It is
presumably involved in hyaluronan
metabolism (Jackson, 2004) but its
exact function remains unclear –
LYVE-1-deficient mice have no obvious
lymphatic vascular malfunctions or mor-
phological abnormalities (G. Thurston,
personal communication). LYVE-1 is
the first marker of lymphatic endothe-
lial competence during development
(Figure 2); in the mature vasculature,
LYVE-1 expression remains high in
lymphatic capillaries while being
downregulated in the collecting lym-
phatic vessels (Makinen et al., 2005).
Podoplanin, a mucin-type trans-
membrane glycoprotein, is expressed
by lymphatic but not by BECs in vivo
and in vitro (Wetterwald et al., 1996;
Breiteneder-Geleff et al., 1999; Kriehu-
ber et al., 2001; Petrova et al., 2002;
Hirakawa et al., 2003). Its biological
function is currently unknown,
although in vitro studies indicated that
podoplanin may be involved in med-
iating cell motility by promoting re-
arrangement of the actin cytoskeleton
(Schacht et al., 2003). Podoplanin null
mice display lymphedema, dilated
lymphatic vessels, and impaired lymph-
atic transport, and they die at birth of
respiratory failure (Ramirez et al.,
2003; Schacht et al., 2003). Therefore,
to further study the role of podoplanin
in postnatal life, it will be essential to
generate tissue-specific knockout mice.
Human podoplanin is recognized by
the D2-40 antibody (Schacht et al.,
2005) and is also expressed by several
non-endothelial cells (Schacht et al.,
2005) and by squamous cell carcino-
mas and certain germ cell tumors
(Martin-Villar et al., 2005; Schacht
et al., 2005), suggesting a potential role
in tumor progression.
The chemokine CCL21, also known
as secondary lymphoid chemokine or
Exodus-2, is secreted by lymphatic
endothelium, but not blood vascular
endothelium (Kriehuber et al., 2001),
and interacts with the CC chemokine
receptor 7. It mediates homing of
lymphocytes and migration of antigen-
stimulated dendritic cells from the
tissues into the lymphatic vessels and
the secondary lymphatic organs, thus
playing an important role in immuno-
regulatory and inflammatory processes.
CCL21 has also been shown to
enhance lymph node metastasis of
CCR-7-expressing malignant melanoma
xenotransplants (Wiley et al., 2001).
Desmoplakin is a cytoplasmic anchor
protein of lymphatic endothelial adhe-
rens junctions that connects intermedi-
ate filaments to the plasma membrane.
Blood vessels do not express desmo-
plakin (Ebata et al., 2001).
Using gene array analysis of LECs
versus BECs, a large number of pre-
viously unknown vascular lineage-
specific genes have been identified
(Petrova et al., 2002; Hirakawa et al.,
2003). Newly identified LEC-specific
genes include macrophage mannose
receptor 1, plakoglobin, integrin a9,
and the chemokine CCL20. The latter,
however, becomes strongly expressed
in both blood vascular and LECs upon
activation (Kriehuber et al., 2001). BEC-
specific genes include VEGFR-1, neuro-
pilin-1, the hyaluronan receptor CD44,
endoglin, adhesion molecules such as
ICAM-1, integrin a5 and N-cadherin,
and several basement membrane, and
extracellular matrix components (col-
lagen IV, versican, laminin, collagen
XIII) (Hirakawa and Detmar, 2004).
Other blood vascular markers include
PAL-E (Skobe and Detmar, 2000) and
CD34 (Hirakawa et al., 2003). The roles
of most of these molecules for the
functional regulation and physiological
maintenance of the two types of vascu-
lature remain to be elucidated.
Newly identified lymphangiogenic
growth factors and receptors
VEGF-C and VEGF-D were originally
cloned as ligands for VEGFR-3 (Joukov
et al., 1996; Orlandini et al., 1996;
Achen et al., 1998), and are presently
the only known ligands for this recep-
tor. VEGF-C promotes proliferation,
migration, and survival of cultured
human LECs (Makinen et al., 2001).
Importantly, transgenic mice over-
expressing VEGF-C or VEGF-D in the
skin show hyperplasia of cutaneous
lymphatic vessels (Jeltsch et al., 1997;
Veikkola et al., 2001) (Table 2),
whereas VEGF-C null mouse embryos
completely lack a lymphatic vascu-
lature and die prenatally of fluid accu-
mulation within the tissues (Karkkainen
et al., 2004). In these mice, the
lymphatically committed venous en-
dothelial cells express Prox1 but are
unable to migrate out to form the initial
lymph sacs. These findings indicate
that LEC specification and subsequent
migration are two separate events, and
that VEGF-C signalling is indispensable
for the latter (Figure 2). VEGF-D also
stimulates lymphangiogenesis in tissues
and tumors (Stacker et al., 2001;
Veikkola et al., 2001). However,
VEGF-D-deficient mice do not exhibit
a lymphatic phenotype (Karkkainen
et al., 2004; Baldwin et al., 2005),
probably because VEGF-D is not ex-
pressed at the critical sites of lymph sac
formation in the embryo (Avantaggiato
et al., 1998; Karkkainen et al., 2004).
Inactivation of VEGFR-3 causes cardi-
ovascular failure and embryonic death
at E9.5 before the emergence of
lymphatic vessels (Dumont et al., 1998),
hampering the analysis of its role in
lymphatic development. Nonetheless,
VEGFR-3 mutations have been identi-
fied in Chy mutant mice that are
characterized by cutaneous lymphede-
ma (Karkkainen et al., 2001), providing
support for an important role of this
gene in lymphatic development and
function. The distinct contributions of
VEGFR-3 versus VEGFR-2 towards
lymphangiogenesis remain at present
unclear, because VEGF-C and VEGF-D –
after enzymatic cleavage – also activate
VEGFR-2, which is expressed by LECs
(Kriehuber et al., 2001; Veikkola et al.,
2001; Hirakawa et al., 2003; Hong
et al., 2004b). Importantly, however,
skin-specific overexpression of a
VEGFR-3-specific mutant of VEGF-C
(VEGF-C156S; Joukov et al., 1998) in
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transgenic mice revealed that activa-
tion of VEGFR-3 signal transduction is
sufficient to promote lymphangio-
genesis (Veikkola et al., 2001).
The possible contribution of VEGF-A
(also named VEGF or vascular perme-
ability factor), to lymphangiogenesis
has been a matter of controversy.
VEGF-A was discovered in 1983 as
the first member of the VEGF family
(Senger et al., 1983) and activates
VEGFR-1 and VEGFR-2. Although
VEGF-A cannot substitute for VEGF-C
to rescue the phenotype of VEGF-C-
deficient mice (Karkkainen et al.,
2004), several recent studies have
established a role of the VEGF-A/
VEGFR-2 signalling pathway in lymph-
angiogenesis. VEGF-A potently in-
duces proliferation of LECs in vitro
(Hirakawa et al., 2003), and injection
of adenoviral murine VEGF-A164 re-
sulted in pronounced and persistent in
vivo lymphangiogenesis in mouse ear
skin (Nagy et al., 2002). Targeted
overexpression of murine VEGF-A164
in the skin of transgenic mice enhanced
lymphangiogenesis as well as angio-
genesis during tissue repair and in skin
inflammation (Kunstfeld et al., 2004;
Hong et al., 2004b). These effects
could be inhibited by a specific
VEGFR-2 blocking antibody, indicating
that VEGF-A signalling through VEGFR-
2 is important for lymphangiogenesis.
However, indirect effects of VEGF-A,
via attraction of inflammatory cells
producing VEGF-C and -D (Cursiefen
et al., 2004; Baluk et al., 2005) might
also contribute to VEGF-A’s lymph-
angiogenic activity (Hirakawa et al.,
2005).
Neuropilins are non-kinase type I
transmembrane proteins that play an
important role in axon guidance within
the nervous system as semaphorin
receptors (Neufeld et al., 2002).
Whereas neuropilin-1 is predominantly
expressed in arterial endothelial cells,
neuropilin-2 is expressed in veins and
lymphatic capillaries (Karkkainen et al.,
2001; Hong et al., 2002; Yuan et al.,
2002). It serves as a co-receptor for
several VEGF family members includ-
ing VEGF-A165, placental growth fac-
tor, and VEGF-C (Gluzman-Poltorak
et al., 2000; Karkkainen et al., 2001).
In addition to neural defects, neuro-
pilin-2-deficient mice show a severe
reduction of small lymphatic vessels,
whereas they develop normal arteries,
veins, and larger collecting lymphatic
vessels (Yuan et al., 2002). The finding
that neuropilin-2 binds VEGF-C raises
the possibility that VEGF-C signalling
through VEGFR-3 may be enhanced by
neuropilin-2, similar to the Nrp1-medi-
ated promotion of VEGF-A signalling
to VEGFR-2 (Soker et al., 1998).
The angiopoietin signalling system is
indispensable for normal blood vessel
development as demonstrated by sev-
eral genetic mouse models (Dumont
et al., 1994; Suri et al., 1996; Maison-
pierre et al., 1997). Angiopoietin-1
(Ang1), an activating ligand for the
endothelial-specific receptor tyrosine
kinase Tie2 (tyrosine kinase with im-
munoglobulin-like loop and epidermal
growth factor homology domains-2)
(Davis et al., 1996), induces lymph-
angiogenesis in the mouse cornea
(Morisada et al., 2005) and – after
adenoviral gene transfer – in other adult
mouse tissues (Tammela et al., 2005).
Transgenic mice overexpressing Ang1
in the skin show cutaneous lymphatic
hyperplasia (Tammela et al., 2005).
The mechanism of these effects re-
mains unclear. Tie2 is expressed in
cultured LECs (Kriehuber et al., 2001;
Petrova et al., 2002) and in the
lymphatic vessels of mice (Morisada
et al., 2005; Tammela et al., 2005),
suggesting that Ang1 might exert direct
effects on lymphatic endothelium.
However, treatment with soluble
VEGFR-3 inhibited the effects of virally
delivered Ang1 in mice, and Ang1
stimulation of LECs resulted in upregu-
lation of VEGFR-3 in vitro and in vivo
(Tammela et al., 2005), indicating that
Ang1 also acts indirectly via the VEGF-
C/VEGFR-3 pathway. Angiopoietin-2,
considered to be an antagonist of Tie2
(Maisonpierre et al., 1997), also ap-
pears to be needed for the normal
formation of the lymphatic vasculature
because angiopoietin-2-deficient mice
have chylous ascites, peripheral
edema, and abnormal patterning of
lymphatic vessels (Gale et al., 2002).
Interestingly, these defects, but not the
blood vascular phenotype, can be
rescued by Ang1 (Gale et al., 2002).
Thus, angiopoietin-2 might act like
Ang1 as an agonist of Tie2 in lymph-
angiogenesis, while it is an (context-
dependent) antagonist of Tie2 in
angiogenesis.
Hepatocyte growth factor (HGF,
also known as scatter factor) was
recently identified as a potent lymph-
angiogenesis factor (Kajiya et al.,
2005). HGF promotes proliferation,
migration, and tube formation of LECs
via its receptor HGF-R. HGF-induced
LEC proliferation was abolished by an
HGF-R blocking antibody but not by
blockade of VEGFR-3, indicating that
HGF exerts its effects independently of
the VEGFR-3 pathway. The promigra-
tory effects of HGF are in part mediated
by the integrin a9, which is specifically
expressed by LECs and is required for
normal lymphatic function (Huang
et al., 2000). Overexpression of HGF
in transgenic mice as well as subcuta-
neous delivery of this growth factor
resulted in increased numbers and
enlargement of lymphatic vessels.
These effects were not inhibited by a
VEGFR-3 blocking antibody (Kajiya
et al., 2005), demonstrating that HGF
can directly promote lymphangio-
genesis in vivo.
Additional lymphangiogenic factors.
Fibroblast growth factor-2 (FGF-2) was
one of the first angiogenic factors
identified and the role of FGFs in
vascular development has been well
characterized (Auguste et al., 2003).
FGF-2 also promotes lymphatic vessel
growth – in addition to blood vessel
growth – in the mouse cornea assay by
inducing VEGF-C secretion from blood
vascular endothelial and perivascular
cells (Kubo et al., 2002; Chang et al.,
2004). FGF-2 might also directly act via
its receptor FGFR-3, which is upregu-
lated by Prox1 in lymphatic endo-
thelium (Shin et al., 2005). FGF-2
enhances migration and proliferation
of primary LECs in vitro, and the
promigratory effect could not be abro-
gated by neutralization of VEGFR-3,
raising the possibility that FGF-2 might
also function independently of the
VEGF-C/VEGFR-3 pathway (Shin
et al., 2005). In addition, recent studies
have suggested that platelet-derived
growth factor-BB (Cao et al., 2004)
and insulin-like growth factors 1 and 2
might also induce lymphangiogenesis
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in the mouse corneal assay (Bjorndahl
et al., 2005), but their potential effects
on skin lymphangiogenesis remain un-
clear. Likely, several lymphangiogenic
growth factors work together in a
complex way, contributing to the pro-
cess of lymphatic vessel formation and
growth in physiological or pathological
conditions (Figure 3).
Genetic basis of lymphedema and new
molecular therapies
Lymphedema is caused by insufficient
lymph transport owing to lymphatic
hypoplasia, impaired lymphatic func-
tion, or obstruction of lymph flow.
Primary lymphedema is characterized
by dilated lymphatic capillaries and
interstitial accumulation of lymph fluid.
In some families, congenital lymph-
edema is linked to the VEGFR-3 locus
on distal chromosome 5q, and missense
mutations in the VEGFR-3 gene have
indeed been identified in several cases
of hereditary, early-onset lymphedema
(Witte et al., 2001). Recent studies have
identified additional mutations in other
genes that are associated with different
human lymphedema syndromes. In
lymphedema-distichiasis, an autoso-
mal-dominant disorder with congenital
lymphedema and double rows of eye-
lashes (distichiasis), inactivating muta-
tions of the FOXC2 gene, a member of
the forkhead/winged-helix family of
transcription factors, were identified in
several families (Fang et al., 2000).
Moreover, mutations of the SOX18
gene on chromosome 20q13, a SRY-
related transcription factor, cause re-
cessive and dominant forms of hypo-
trichosis–lymphedema–telangiectasia
syndrome. Mutations in the DNA-bind-
ing domain of SOX18 have been found
in the recessive form of the disease
whereas the dominant hereditary form
is caused by a heterozygous nonsense
mutation of the transactivation domain
(Irrthum et al., 2003). An involvement
of Sox18 in lymphatic vessel develop-
ment is further supported by the phe-
notype of ragged mice that develop
lymphedema and also show abnormal-
ities of the hair coat (Table 2).
Based on its potent lymphangio-
genic effect, VEGF-C has been tested
for gene and protein therapy of lymph-
edema in animal models. Adeno-
associated virus-mediated VEGF-C
gene therapy promoted lymphatic ves-
sel generation in the skin of Chy
lymphedema mice (Karkkainen et al.,
2001). Importantly, VEGF-C156S, a
mutant form of VEGF-C that selectively
activates VEGFR-3, successfully in-
duced the formation of a functional
cutaneous lymphatic vessel network
without blood vessel growth or vascu-
lar leakiness, side effects observed with
VEGF-C gene therapy due to its activa-
tion of VEGFR-2 (Saaristo et al., 2002).
Recently, successful regeneration of a
lymphatic network was observed after
injection of VEGF-C protein in a
surgical lymphedema model in the
rabbit ear, indicating the potential use
of VEGF-C for the treatment of second-
ary lymphedema (Skobe et al., 2001).
Tumor lymphangiogenesis and
metastasis
Tumor metastasis to regional lymph
nodes represents the first step of tumor
dissemination in most skin cancers
and also serves as a major prognostic
indicator for disease progression. Little
is known, however, about the mechan-
isms how tumor cells gain entry into
the lymphatic system, and it has been
generally thought that lymphatic inva-
sion only occurs once infiltrating tumor
cells happen upon pre-existing peritu-
moral lymphatic vessels. Recent studies
in animal tumor models have now
provided direct experimental evidence
that increased levels of VEGF-C and/or
VEGF-D promote active tumor lymph-
angiogenesis and lymphatic tumor
spread to regional lymph nodes, and
that these effects can be suppressed by
blocking VEGFR-3 signalling (Mandrio-
ta et al., 2001; Skobe et al., 2001;
Stacker et al., 2001; He et al., 2002).
Very recently, we have found that
VEGF-A also acts as a potent tumor
lymphangiogenesis factor and that tu-
mor-derived VEGF-A promotes expan-
sion of the lymphatic network within
VEGFR-2 VEGFR-3 FGFR-3Nrp2
Tie2
HGF-R
IGF-1R
PDGFR /
Indu
ction
Induction
Lymphatic vessel
Lymphangiogenesis
?VEGF-A
VEGF-D
FGF-2
IGF-1
IGF-2
HGF
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Ang2VEGF-C
PDGF-BB
Figure 3. Schematic representation of lymphangiogenic growth factors and their receptors expressed by lymphatic endothelium. Several vascular
endothelial growth factors (VEGF-A, VEGF-C, VEGF-D) promote lymphangiogenesis by activation of distinct VEGFRs and Nrp2. FGF-2 acts directly
through FGFR-3 and also via induction of VEGF-C. Angiopoietin-1 (Ang1) activates Tie2 and up-regulates VEGFR-3. HGF, insulin-like growth factors (IGF),
and platelet-derived growth factor-BB (PDGF-BB) act directly through their respective receptors HGF-R, IGF-1R, and PDGFR.
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draining, sentinel lymph nodes, even
before these tumors metastasized
(Hirakawa et al., 2005). These novel
findings indicate that lymph node
lymphangiogenesis might contribute
to the further metastatic tumor spread
beyond the sentinel lymph node. Im-
portantly, a large number of clinico-
pathological studies have shown a
direct correlation between expression
of VEGF-C or VEGF-D by tumor cells
and metastatic tumor spread in many
human cancers, indicating an impor-
tant role of lymphangiogenesis also in
human tumor progression (Stacker
et al., 2002). Our own recent studies
in human cutaneous malignant mela-
nomas demonstrated – for the first time
– the presence of both intratumoral
and peritumoral lymphangiogenesis
(Dadras et al., 2003). They also showed
that primary melanomas that later
metastasized were characterized by
increased lymphangiogenesis – as com-
pared to non-metastatic tumors – and
that the degree of tumor lymphangio-
genesis can serve as a novel predictor
of lymph node metastasis and overall
patient survival, independently of tu-
mor thickness. Tumor lymphangio-
genesis also significantly predicted the
presence of sentinel lymph node me-
tastases at the time of surgical excision
of the primary melanoma (Dadras
et al., 2005). Further studies involving
larger numbers of cases are needed to
confirm these findings.
New insights into the pathogenesis of
Kaposi’s sarcoma
Kaposi’s sarcoma (KS) is the most
frequently occurring malignant tumor
in patients infected with the human
immunodeficiency virus. KS mainly
affects the skin and forms lesions of
various types, including early inflam-
matory and patch stage lesions, and
tumors with a predominant population
of spindle cells. Infection with KS-
associated herpesvirus (also known as
human herpesvirus-8) is essential for KS
tumor formation. KS has been consid-
ered to be a neoplasm of KS-associated
herpesvirus-infected lymphatic en-
dothelium, owing to the morphological
characteristics of the tumor cells and
their expression of several lymphatic
lineage-specific genes including
VEGFR-3 and podoplanin. Recently,
we and others have shown that infec-
tion of differentiated BECs with KS-
associated herpesvirus leads to their
LEC re-programming with induction of
approximately 70% of the major lym-
phatic lineage-specific genes including
Prox1, a master regulator of lymphatic
development, and downregulation of
blood vascular genes (Wang et al.,
2004; Hong et al., 2004a). Together,
these results provide a molecular ex-
planation for the previously observed
controversial results regarding the line-
age-specific differentiation of KS cells.
Inflammation and lymphangiogenesis
There is increasing evidence that
lymphatic vessels actively participate
in acute and chronic inflammation,
as well as in the cutaneous response
to UVB irradiation. Psoriatic skin le-
sions are characterized by pronounced
lymphatic hyperplasia (Kunstfeld et al.,
2004), and chronic skin inflammation
in mice is also associated with LEC
proliferation and lymphatic hyperplasia
(Kunstfeld et al., 2004). Furthermore,
kidney transplant rejection is frequently
accompanied by lymphangiogenesis,
and LEC-derived chemokines such
as CCL21 might actively promote the
inflammatory process (Kerjaschki et al.,
2006). Recently, we found that acute
UVB irradiation of the skin results in
hyperpermeable, leaky lymphatic ves-
sels that are functionally impaired
(Kajiya and Detmar, 2006). Impor-
tantly, blockade of VEGFR-3 resulted
in prolonged inflammation and edema
after UVB irradiation. Together, these
results indicate that lymphatic vessels
are not only required to drain inflam-
mation-associated tissue edema, but
might also actively participate in the
maintenance of chronic inflammatory
diseases.
Perspectives
Although traditionally neglected as a
topic of scientific study, the lymphatic
vascular system has recently received
tremendous scientific interest (Brown,
2005). Owing to a number of recent
discoveries, some of the mechanisms
controlling the normal and patho-
logical development of the lymphatic
vasculature are now being unravelled,
and several genetic defects have been
identified in patients with lymph-
edema. The identification of specific
markers and growth factors for lympha-
tic vessels have been instrumental in
this advance. The recently proposed
concept of tumor lymphangiogenesis
and its role in tumor metastasis is of
particular importance for the under-
standing of cancer progression. Further
progress in this field will likely lead to
a better diagnosis and treatment of a
variety of lymphatic disorders but also
of certain types of skin cancer and of
inflammatory skin diseases.
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